MaxCyte to buy Akron Bio for $151.8M and secures up to $75M MidCap credit facility
MaxCyte (NASDAQ: MXCT) announced on November 10, 2026 a definitive agreement to acquire Akron BioProducts, a supplier of GMP-grade reagents and ancillary materials for cell therapy manufacturing, from Arcline Investment Management. Consideration is $105M in cash, about 20.6M MaxCyte shares and $20M in deferred payments, with closing expected before the end of 2026 and no stockholder approval needed. MaxCyte also arranged a MidCap Financial facility of up to $75M, and the combined company's products are referenced in drug master files supporting five approved therapies and over 100 clinical programs.
Company's press release (SEC filing): Maxcyte, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597
Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants
Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities
Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds
